Proteolysis-targeting chimeras (PROTACs), heterobifunctional compounds that consist of
protein-targeting ligands linked to an E3 ligase recruiter, have arisen as a powerful …

Co-opting Cullin4 RING ubiquitin ligases (CRL4s) to inducibly degrade pathogenic proteins
is emerging as a promising therapeutic strategy. Despite intense efforts to rationally design …

Therapeutic Strategy” in May 2017. Since a large portion of the proteome lacks a small
molecule ligand or enzymatic active site, there has been much interest in the development of …

Target-protein degradation is an emerging field in drug discovery and development. In
particular, the substrate-receptor proteins of the cullin–ubiquitin ligase system play a key …

Targeted proteasomal and autophagic protein degradation, often employing bifunctional
modalities, is a new paradigm for modulation of protein function. In an attempt to explore …

Errors in protein folding may result in premature clearance of structurally aberrant proteins,
or in the accumulation of toxic misfolded species or protein aggregates. These pathological …

Targeted protein degraders such as PROTACs and molecular glues are a rapidly emerging
therapeutic modality within industry and academia. Degraders possess unique mechanisms …

Targeted protein degradation represents an area of great interest, potentially offering
improvements with respect to dosing, side effects, drug resistance, and reaching …

Induced protein degradation accomplishes elimination, rather than inhibition, of pathological
proteins. Key to the success of this novel therapeutic modality is the modification of proteins …

Engineered destruction of target proteins by recruitment to the cell's degradation machinery
has emerged as a promising strategy in drug discovery. The majority of molecules that …